InnoCan Pharma Corporation (CSE:INNO)

Market Cap	102.63M
Revenue (ttm)	39.32M
Net Income (ttm)	-2.15M
Shares Out	6.04M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Average Volume	1,041
Open	18.00
Previous Close	17.52
Day's Range	17.00 - 18.00
52-Week Range	9.75 - 21.00
Beta	0.10
RSI	49.95
Earnings Date	Nov 20, 2025

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for e...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 5
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: INNO

Financial Performance

In 2024, InnoCan Pharma's revenue was $29.44 million, an increase of 115.55% compared to the previous year's $13.66 million. Losses were -$1.83 million, -60.98% less than in 2023.

Financial numbers in USD